DUZALLO Trademark

Trademark Overview

On Wednesday, June 27, 2018, a trademark application was filed for DUZALLO with the United States Patent and Trademark Office. The USPTO has given the DUZALLO trademark a serial number of 88017647. The federal status of this trademark filing is REGISTERED as of Tuesday, July 16, 2019. This trademark is owned by AstraZeneca AB. The DUZALLO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for use in the treatment of hyperuricemia associated with gout
duzallo

General Information

Serial Number88017647
Word MarkDUZALLO
Filing DateWednesday, June 27, 2018
Status700 - REGISTERED
Status DateTuesday, July 16, 2019
Registration Number5803545
Registration DateTuesday, July 16, 2019
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 30, 2019

Trademark Statements

Description of MarkThe mark consists of two interlocking rhombi with rounded corners positioned to the left of and level with the term "DUZALLO".
Goods and ServicesPharmaceutical preparations and substances for use in the treatment of hyperuricemia associated with gout
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 2, 2018
Primary Code005
First Use Anywhere DateFriday, October 6, 2017
First Use In Commerce DateFriday, October 6, 2017

Trademark Owner History

Party NameAstraZeneca AB
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressSödertälje SE-15185
SE
Party NameAstraZeneca AB
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSödertälje SE-15185
SE
Party NameAstraZeneca AB
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSödertälje SE-15185
SE

Trademark Events

Event DateEvent Description
Monday, August 6, 2018ASSIGNED TO EXAMINER
Monday, August 6, 2018SUSPENSION LETTER WRITTEN
Monday, August 6, 2018LETTER OF SUSPENSION E-MAILED
Saturday, June 30, 2018NEW APPLICATION ENTERED
Monday, July 2, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 3, 2018NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, August 6, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, February 28, 2019ASSIGNED TO LIE
Friday, March 15, 2019TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, February 8, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, March 1, 2019SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sunday, March 3, 2019SUSPENSION INQUIRY WRITTEN
Sunday, March 3, 2019INQUIRY TO SUSPENSION E-MAILED
Sunday, March 3, 2019NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Saturday, March 16, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, March 16, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 18, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 10, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 30, 2019PUBLISHED FOR OPPOSITION
Tuesday, April 30, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 16, 2019REGISTERED-PRINCIPAL REGISTER
Thursday, August 8, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, March 18, 2019DATA MODIFICATION COMPLETED
Thursday, August 8, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 22, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 22, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, July 22, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 22, 2021TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Thursday, July 22, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 22, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 16, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

duzallo associated gout hyperuricemia treatment preparations substances pharmaceutical